[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338169-105":59,"doc-detail-338169-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","recent-progress-of-cdk46-inhibitors-current-practice-in-breast-cancer","Recent progress of CDK4/6 inhibitors’ current practice in breast cancer","","Recent progress of CDK4/6 inhibitors in breast cancer reviews how dysregulated CDK4/6 signaling drives uncontrolled proliferation in hormone receptor-positive, HER2-negative advanced disease. The work summarizes FDA-approved CDK4/6 inhibitor use combined with endocrine therapy, highlighting improvements in progression-free survival. It also evaluates treatment strategies across endocrine-sensitive and other subpopulations and discusses therapeutic directions after progression during CDK4/6 inhibitor therapy, integrating preclinical and clinical evidence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-progress-of-cdk46-inhibitors-current-practice-in-breast-cancer/338169/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-progress-of-cdk46-inhibitors-current-practice-in-breast-cancer/338169.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are CDK4/6 inhibitors important in hormone receptor-positive, HER2-negative advanced breast cancer?","Question",{"text":112,"@type":113},"Aberrant CDK4/6 pathway activation promotes uncontrolled proliferation, and combining CDK4/6 inhibitors with endocrine therapy improves outcomes such as progression-free survival compared with endocrine therapy alone.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which endocrine-sensitive patients are included in the review’s definition?",{"text":117,"@type":113},"The review describes endocrine-sensitive populations as patients with relapse after completing adjuvant endocrine therapy more than one year, and endocrine-naive patients with recurrent advanced breast cancer who previously did not receive endocrine therapy or adjuvant endocrine therapy after radical surgery.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment strategies are addressed regarding CDK4/6 inhibitors?",{"text":121,"@type":113},"The review systematically evaluates utilization strategies across breast cancer subpopulations and explores potential therapeutic avenues after disease progression during CDK4/6 inhibitor therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338169,1790913849,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Gene [Therapy](Therapy www.nature.com/cgt)[ www.nature.com/cgt](Therapy www.nature.com/cgt)  \nREVIEW ARTICLE OPEN   \nRecent progress of CDK4/6 inhibitors’ current practice in breast cancer  \nXueqing Wang 1,4, Shanshan Zhao 1,4, Qinghan Xin2,4, Yunkun Zhang3,4, Kainan Wang 1 ✉ and Man Li 1 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Dysregulated cellular proliferation represents a hallmark feature across all cancers. Aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway, independent of mitogenic signaling, engenders uncontrolled breast cancer cell proliferation. Consequently, the advent of CDK4/6 inhibition has constituted a pivotal milestone in the realm of targeted breast cancer therapy. The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has emerged as the foremost therapeutic modality for patients afﬂicted with hormone receptor-positive (HR + )/HER2-negative (HER2-) advanced breast cancer. At present, the Food and Drug Administration (FDA) has sanctioned various CDK4/6i for employment as the primary treatment regimen in HR + /HER2-breast cancer. This therapeutic approach has demonstrated a substantial extension of progression-free survival (PFS), often amounting to several months, when administered alongside endocrine therapy. Within this comprehensive review, we systematically evaluate the utilization strategies of CDK4/6i across various subpopulations of breast cancer and explore potential |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| therapeutic avenues following disease progression during application of CDK4/6i therapy. |  |  |\n|  | Cancer Gene Therapy (2024) 31:1283–1291; [https://doi.org/10.1038/s41417-024-00747-x](https://doi.org/10.1038/s41417-024-00747-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nBreast cancer ranks as the most common cancer among women globally, accounting for 31% of all female cancers. It stands as the second leading cause of cancer-related fatalities in women [1, 2] . Within the spectrum of breast cancer subtypes, HR+ luminal-like tumors, including luminal A and B, represent the most prevalent category, encompassing 60–70% of all cases. For these tumors, ET serves as the primary ﬁrst-line treatment in cases of advanced or metastatic breast cancer (MBC) . However, the development of ET resistance is an inevitable challenge. Therefore, CDK4/6i have recently emerged as a clinically signiﬁcant and well-tolerated therapeutic option for patients with MBC.  \nIn estrogen receptor (ER)-positive breast cancer, activation of the ER signaling pathway upregulates the ER-cyclin D-CDK4/6 pathway. Cyclin-CDKs pathway plays a pivotal role in cell-cycle regulation [3] . When bound and activated by cyclin D, CDK4/6 phosphorylates the retinoblastoma protein (Rb), leading to the release of the transcription factor E2F. This promotes the transcription of genes related to the cell cycle, driving the transition of cells from the G1 phase to the S phase [4–8] . Therefore, the inhibition of both CDK4/6 and ER have shown clinical efﬁcacy in ER+ advanced breast cancer [9] . Currently, the USA FDA has approved three CDK4/6i: Palbociclib (Pﬁzer), Abemaciclib (Eli Lilly), and Ribociclib (Novartis) . Furthermore, the China FDA has approved Dalpiciclib (Herngri) for the ﬁrst- and second-line treatment of HR + /HER2- advanced breast cancer [10] . Considering the effectiveness of CDK4/6i in HR + /HER2-MBC treatment, these drugs are now under investigation in various breast cancer subtypes and different clinical scenarios. For  \ninstance, several preclinical studies have indicated that CDK4/6i can boost tumor cell immunogenicity, leading to the exploration of CDK4/6i and Immune checkpoint inhibitor (ICI) combinations [11, 12] . In this review, we compile the most recent preclinical and clinical evidence concerning the application of CDK4/6i in breast cancer and elaborate on the treatment strategies, and advantag","cbCaiooY7N58rA4o","https://ap.wps.com/l/cbCaiooY7N58rA4o","pdf",961951,"English","# Introduction\n# CDK4/6I combined with ET in HR + /HER2-advanced breast cancer\n## Application in Endocrine-sensitive population\n## Clinical trial summary (Table 1)","[{\"question\":\"Why are CDK4/6 inhibitors important in hormone receptor-positive, HER2-negative advanced breast cancer?\",\"answer\":\"Aberrant CDK4/6 pathway activation promotes uncontrolled proliferation, and combining CDK4/6 inhibitors with endocrine therapy improves outcomes such as progression-free survival compared with endocrine therapy alone.\"},{\"question\":\"Which endocrine-sensitive patients are included in the review’s definition?\",\"answer\":\"The review describes endocrine-sensitive populations as patients with relapse after completing adjuvant endocrine therapy more than one year, and endocrine-naive patients with recurrent advanced breast cancer who previously did not receive endocrine therapy or adjuvant endocrine therapy after radical surgery.\"},{\"question\":\"What treatment strategies are addressed regarding CDK4/6 inhibitors?\",\"answer\":\"The review systematically evaluates utilization strategies across breast cancer subpopulations and explores potential therapeutic avenues after disease progression during CDK4/6 inhibitor therapy.\"}]","Recent progress of CDK4/6 inhibitors’ current practice in breast cancer | PDF",1790022324,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a910e8a1cbc4436030dec0f276878b4.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d31920ce3a93275387bbb29e0e6d0da.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/935698fa1573a8c287497079a306c3de.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/485e39415b17bc45efca6391467ca648.webp",980,1301]